BioSight
Companies
Viatris Inc logo

VTRS

NASDAQCANONSBURG, PA
Viatris Inc

The excerpt provided does not contain specific information about Viatris Inc's therapeutic areas, drug modalities, development stages, or lead programs. The text focuses exclusively on financial matters including stock trading, dividend payments, share repurchases, and stock performance comparisons, without discussing the company's pharmaceutical pipeline or product portfolio.

$14.94+85.65%1Y
VTRS · daily close · illustrative · 0 catalysts marked
$7.24$9.63$12$14$17Apr '25Aug '25Dec '25Apr '26
1Y high$16.001Y low$8.04range$7.96(99%)past catalysts

Pipeline1

Cenerimod
Phase 3Lupus Erythematosus, Systemic
Phase 3Nephritis, Lupus
small-molecule

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar